|
DE69333624T2
(de)
|
1992-05-19 |
2005-09-15 |
Novogen Research Pty. Ltd., North Ryde |
Verwendung von isoflavon phyto-östrogen extrakten von soja oder klee
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
AUPO203996A0
(en)
|
1996-08-30 |
1996-09-26 |
Novogen Research Pty Ltd |
Therapeutic uses
|
|
GT199800127A
(es)
*
|
1997-08-29 |
2000-02-01 |
|
Combinaciones terapeuticas.
|
|
BR9815745A
(pt)
*
|
1998-03-17 |
2000-11-14 |
Warner Lambert Co |
Combinações de inibidor de metaloproteinase de matriz estatina
|
|
US6489366B1
(en)
|
1998-12-23 |
2002-12-03 |
G. D. Searle, Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
|
|
AU2007200367B2
(en)
*
|
1999-02-06 |
2010-04-08 |
Astrazeneca Ab |
Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
|
|
GB0001662D0
(en)
|
1999-02-06 |
2000-03-15 |
Zeneca Ltd |
Pharmaceutical compositions
|
|
PL353199A1
(en)
|
1999-08-30 |
2003-11-03 |
Aventis Pharma Deutschland Gmbh |
Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
|
|
AUPQ266199A0
(en)
|
1999-09-06 |
1999-09-30 |
Novogen Research Pty Ltd |
Compositions and therapeutic methods involving isoflavones and analogues thereof
|
|
DE19944803A1
(de)
*
|
1999-09-20 |
2001-03-29 |
Bayer Ag |
Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
|
|
FR2803525B1
(fr)
*
|
2000-01-06 |
2002-05-03 |
Sod Conseils Rech Applic |
Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
|
|
AR030414A1
(es)
*
|
2000-04-03 |
2003-08-20 |
Astrazeneca Ab |
Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
|
|
GB2361185A
(en)
|
2000-04-10 |
2001-10-17 |
Nicholas J Wald |
Pharmaceutical formulation for the prevention of cardiovascular disease
|
|
SE0002354D0
(sv)
*
|
2000-06-22 |
2000-06-22 |
Astrazeneca Ab |
New formulation
|
|
BR0112665A
(pt)
|
2000-07-19 |
2003-06-24 |
Novartis Ag |
Sais
|
|
WO2002017913A1
(en)
*
|
2000-08-30 |
2002-03-07 |
Sankyo Company, Limited |
Medicinal compositions for preventing or treating heart failure
|
|
US7018649B2
(en)
*
|
2000-10-23 |
2006-03-28 |
Euro-Celtique, S.A. |
Felodipine transdermal device and methods
|
|
US8168616B1
(en)
|
2000-11-17 |
2012-05-01 |
Novartis Ag |
Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
|
|
US6982251B2
(en)
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
AUPR255401A0
(en)
*
|
2001-01-16 |
2001-02-08 |
Novogen Research Pty Ltd |
Regulation of lipids and/or bone density and compositions therefor
|
|
US7071181B2
(en)
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
AR035533A1
(es)
|
2001-01-26 |
2004-06-02 |
Schering Corp |
Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
|
|
IL156445A0
(en)
|
2001-01-26 |
2004-01-04 |
Schering Corp |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
AUPR363301A0
(en)
|
2001-03-08 |
2001-04-05 |
Novogen Research Pty Ltd |
Dimeric isoflavones
|
|
UA76475C2
(en)
*
|
2001-07-19 |
2006-08-15 |
Pharmacia Corp |
Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system
|
|
PE20030324A1
(es)
*
|
2001-07-31 |
2003-04-03 |
Warner Lambert Co |
Composiciones farmaceuticas de amlodipina y atorvastatina
|
|
US6852737B2
(en)
*
|
2001-08-06 |
2005-02-08 |
Recordati Ireland Limited |
Crude and crystalline forms of lercanidipine hydrochloride
|
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
MXPA04002573A
(es)
|
2001-09-21 |
2004-06-18 |
Schering Corp |
Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
|
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
|
BR0306643A
(pt)
|
2002-01-17 |
2004-10-19 |
Pharmacia Corp |
Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
|
|
CA2490636A1
(en)
*
|
2002-06-20 |
2003-12-31 |
The Governors Of The University Of Alberta |
Dichloroacetate in combination with cardioprotective or hemodynamic drugs
|
|
JP2005533822A
(ja)
*
|
2002-06-27 |
2005-11-10 |
エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド |
臭化水素酸カルベジロール
|
|
KR101468827B1
(ko)
*
|
2002-06-27 |
2014-12-03 |
스미스클라인 비이참 (코르크) 리미티드 |
카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
|
|
US20040053842A1
(en)
*
|
2002-07-02 |
2004-03-18 |
Pfizer Inc. |
Methods of treatment with CETP inhibitors and antihypertensive agents
|
|
US7071210B2
(en)
*
|
2002-07-02 |
2006-07-04 |
Pfizer Inc. |
CETP inhibitors in combination with antihypertensive agents and uses thereof
|
|
GB0221579D0
(en)
*
|
2002-09-17 |
2002-10-23 |
Pfizer Ltd |
Combinations of atorvastatin and, adrenergic receptor antagonists
|
|
JP2006504800A
(ja)
*
|
2002-10-16 |
2006-02-09 |
レコーダチ アイルランド リミテッド |
リシノプリル／レルカニジピンの組み合わせ治療
|
|
WO2004043457A1
(en)
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
|
CA2517572C
(en)
|
2003-03-07 |
2011-12-13 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
JP2006519869A
(ja)
|
2003-03-07 |
2006-08-31 |
シェーリング コーポレイション |
置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
EP1601668B1
(en)
|
2003-03-07 |
2008-08-27 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
GB0322552D0
(en)
|
2003-09-26 |
2003-10-29 |
Astrazeneca Uk Ltd |
Therapeutic treatment
|
|
JP2007512350A
(ja)
*
|
2003-11-25 |
2007-05-17 |
エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド |
カルベジロール組成物の治療および送達方法
|
|
US8734850B2
(en)
*
|
2003-11-25 |
2014-05-27 |
Flamel Technologies |
Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
|
|
EP1686986A4
(en)
*
|
2003-11-25 |
2009-05-27 |
Sb Pharmco Inc |
CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
|
|
KR20050092519A
(ko)
*
|
2004-03-16 |
2005-09-22 |
화이자 인코포레이티드 |
아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
|
|
WO2005099700A1
(en)
*
|
2004-04-06 |
2005-10-27 |
Merck & Co., Inc. |
Methods for the treatment of hypertension
|
|
ES2282062T1
(es)
|
2004-06-04 |
2007-10-16 |
Teva Pharmaceutical Industries Ltd. |
Composicion farmaceutica que contiene irbesartan.
|
|
EP1781265B1
(en)
|
2004-08-25 |
2010-04-07 |
Essentialis, Inc. |
Pharmaceutical formulations of potassium atp channel openers and uses thereof
|
|
KR20070111468A
(ko)
*
|
2005-02-17 |
2007-11-21 |
키에시 파르마슈티시 엣스. 피. 에이. |
마니디핀과 스타틴의 치료용 복합물
|
|
CA2645281A1
(en)
|
2006-03-29 |
2007-10-04 |
Kowa Co., Ltd. |
Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
|
|
US8642083B2
(en)
*
|
2006-10-30 |
2014-02-04 |
Hanall Biopharma Co., Ltd. |
Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
|
|
US20110117194A1
(en)
|
2008-04-29 |
2011-05-19 |
Hanall Biopharma Co., Ltd. |
Pharmaceutical formulation containing angiotensin-ii receptor blocker
|
|
CZ2008740A3
(cs)
*
|
2008-11-24 |
2010-01-06 |
Zentiva, A.S. |
Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
|
|
MY173823A
(en)
*
|
2009-01-23 |
2020-02-24 |
Hanmi Science Co Ltd |
Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
|
|
SI23149A
(sl)
*
|
2009-09-21 |
2011-03-31 |
Silverstone Pharma |
Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
|
|
RU2481124C1
(ru)
*
|
2011-10-27 |
2013-05-10 |
Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" |
Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
|
|
CN102671198A
(zh)
*
|
2011-12-17 |
2012-09-19 |
东莞达信生物技术有限公司 |
一种降压降脂复方药及其制备方法
|
|
KR20140028971A
(ko)
*
|
2012-08-31 |
2014-03-10 |
한미약품 주식회사 |
아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
|
|
WO2014142521A1
(ko)
*
|
2013-03-12 |
2014-09-18 |
주식회사 엘지생명과학 |
발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법
|
|
CN104173420A
(zh)
*
|
2013-05-20 |
2014-12-03 |
广州诺氏刘生物科技有限公司 |
一种治疗急性肾衰竭的药物
|
|
WO2016065103A1
(en)
|
2014-10-23 |
2016-04-28 |
Arena Pharmaceuticals, Inc. |
Method of treating conditions related to the pgi2 receptor
|
|
CN108156807A
(zh)
*
|
2015-06-30 |
2018-06-12 |
韩美药品株式会社 |
含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
|
|
FR3040303B1
(fr)
*
|
2015-08-27 |
2019-04-05 |
Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger |
Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
|
|
CN105232555A
(zh)
*
|
2015-11-19 |
2016-01-13 |
哈尔滨圣吉药业股份有限公司 |
一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
|
|
JP2019517482A
(ja)
*
|
2016-06-02 |
2019-06-24 |
アナ ファーマシューティカルズ， インコーポレイテッドＡｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
高カルシウム尿症及び腎結石症の治療方法及び治療用組成物
|
|
KR20240096848A
(ko)
|
2017-01-25 |
2024-06-26 |
더 조지 인스티튜트 포 글로벌 헬스 |
고혈압의 치료를 위한 조성물
|
|
US12521380B2
(en)
|
2017-01-25 |
2026-01-13 |
The George Institute for Global Health |
Compositions for the treatment of hypertension
|
|
EP3977985B1
(en)
|
2017-03-01 |
2023-09-06 |
Arena Pharmaceuticals, Inc. |
Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
|
|
WO2019222764A1
(en)
|
2018-05-16 |
2019-11-21 |
Arena Pharmaceuticals, Inc. |
Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
|
|
MX2021001043A
(es)
*
|
2018-07-26 |
2021-04-12 |
The George Inst For Global Health |
Composiciones para el tratamiento de hipertension.
|
|
CN112826937B
(zh)
*
|
2021-03-25 |
2022-03-22 |
山东大学齐鲁医院 |
艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用
|